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Abstract
West Nile virus (WNV) is a zoonotic virus, which is transmitted by mosquitoes. It is
the causative agent of the disease syndrome called West Nile fever. In some
human cases, a WNV infection can be associated with severe neurological
symptoms. The immune response to WNV is multifactorial and includes both
humoral and cellular immunity. T-cell epitope mapping of the WNV envelope (E)
protein has been performed in C57BL/6 mice, but not in BALB/c mice. Therefore,
we performed in BALB/c mice a T-cell epitope mapping using a series of peptides
spanning the WNV envelope (E) protein. To this end, the WNV-E specific T cell
repertoire was first expanded by vaccinating BALB/c mice with a DNA vaccine that
generates subviral particles that resemble West Nile virus. Furthermore, the WNV
structural protein was expressed in Escherichia coli as a series of overlapping 20-
mer peptides fused to a carrier-protein. Cytokine-based ELISPOT assays using
these purified peptides revealed positive WNV-specific T cell responses to peptides
within the different domains of the E-protein.
Introduction
West Nile virus (WNV) is a small enveloped single-stranded positive sense RNA-
containing virus that belongs to the family Flaviviridae [1]. The virus is
maintained in an enzootic cycle where it is transmitted between ornithophilic
mosquitoes of the Culex genus and birds. Equine and humans are considered
dead-end hosts since they do not mount high enough viremia for mosquitoes to
become infected following feeding [2]. Human infection with the virus leads to a
wide range of diseases from mildly febrile to severe neurologic complications and
death, but asymptomatic infections occur most frequently [3]. Humoral
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immunity is considered an essential aspect of protective immunity since it limits
WNV dissemination into the nervous system. This was demonstrated in mice
lacking B cells which developed high-grade viremia, early dissemination into the
brain and uniform mortality [4]. The envelope E glycoprotein is the principal
antigen that elicits neutralizing antibodies and as such is a primary target for
vaccine development [5]. Studies in animal models have also demonstrated that T
lymphocytes are an essential component of protection against WNV. Mice
deficient in CD8+ T cells develop persistent WNV infections in the brain [6, 7].
Studies in mice have also shown that CD4+ T cells control WNV infection by
priming B cell and antibody responses, and by sustaining CD8+ T cell activity [8].
Mapping of antigenic peptide sequences from proteins of relevant pathogens
recognized by T helper (Th) and by cytolytic T lymphocytes (CTL) may help to
understand virus immunity and pathogenesis. The majority of T cells recognize
peptide epitopes bound to major histocompatibility complex (MHC)-encoded
glycoproteins on the surface of professional antigen-presenting cells APC [9].
Most T cells are specific for peptide epitopes in association with either classical
MHC class I molecules (H2-K, D, and L in mice) in the case of CD8+ T cells, or
class II molecules (H2-A and E in mice) for CD4+ T cells [10]. These peptide
antigens are subsequently detected by the T cell receptor of T cells, which
proliferate, secrete cytokines and differentiate into antigen-specific effector cells
[11, 12]. Nearly all of the epitopes associated with protective responses against
WNV using mice models are non-linear and conformational B-cell epitopes and
most of these are specific to the envelope (E) protein. The majority of these B-cell
epitopes have been defined in BALB/c mice [13] whereas C57BL/6 mice have been
used mostly to identify T-cell epitopes [13–16]. Both mouse strains are equally
susceptible to WNV infection [17, 18] but C57BL/6 mice demonstrate elevated
blood-brain barrier permeability [17]. In addition, as C57BL/6 mice predomi-
nantly show Th1-dependent immune responses upon infection, whereas BALB/c
mice tend to favor Th2-responses, T-cell epitopes identified in one strain might
not be directly transferable to the other.
Bioinformatics experts have developed computer-driven algorithms methods to
predict T cell epitopes which have significantly decreased the experimental burden
that is associated with epitope identification [11, 19–21]. To predict in BALB/c
mice potential T-cell epitopes of the E-protein of the WNV, we used the Immune
Epitope Database and Analysis Resource (IEDB, [22]). To confirm these
predictions with in vivo immunogenicity, we vaccinated BALB/c mice with a
plasmid expressing the membrane protein M (prM) and E protein. Subsequently,
we measured the CD8+ and CD4+ T cell cytokine responses using a series of
peptides derived from WNV E-protein. As the DNA vaccine leads to the
expression of virus-like-particles resembling correctly folded E and M proteins, we
can assume that the identified epitopes will also exist during the course of a WNV
infection [23].
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Findings
The sequence spanning the E protein of the lineage 1 WNV strain ‘‘Ita09’’ (NCBI
Acc#.210 GU011992) was separated into 26 clones, each coding for 30 amino acid
long peptides with an overlap of 10 amino acids on both sides. The DNA
fragments encoding these peptides were cloned in the bacterial expression vector
pEXP1 by ATG:biosynthetics (Freiburg, Germany) after the sequence of
glutathione-S-transferase (GST) from Schistosoma japonicum. The sequence of the
different bacterial expression vectors were sequenced to ensure that they
contained the right base pair sequences and hence encoded the desired peptides.
After transformation of these vectors into the E. coli BL21 strain, selected colonies
were grown in Luria Bertani broth containing kanamycine and induced overnight
with isopropylthio-b-galactoside (IPTG, 1 mM final concentration, Sigma–
Aldrich (Diegem, Belgium)). The bacteria were collected by centrifugation
(20 min at 4,000 g at 4 C˚) and the cell pellet was resuspended in lysis buffer
(phosphate buffered saline (PBS, Invitrogen (Merelbeke, Belgium)) containing
protease inhibitors cocktail (Roche, Mannheim, Germany), 1 mM DTT, 1 mM
EDTA, 1% Triton X-100 and Lysozyme (1 mg/ml)). Lysates were obtained after
sonication and were subsequently clarified by centrifugation (30 min at 15,0006g
at 4 C˚). Recombinant peptides derived from the E-protein were purified by
glutathione affinity purification and dialyzed against sterile PBS before use. The
purified proteins were analyzed in denaturing protein gels and the size difference
compared to GST alone was visualized as previously described by Chabierski et al.
[24]. The expression levels were very high to low (Table 1 and Fig. 1).
From six clones the amount of protein obtained was not sufficient to be used as
stimulant in ELISPOT assays. To expand the WNV-E specific T-cell repertoire,
five BALB/c mice were intramuscularly immunized (two vaccinations with four-
weeks interval) followed by in vivo electroporation (BTX ECM 830, Harvard
apparatus, Holliston, MA, USA) of a plasmid encoding the prM/E expression
cassette [23]. This plasmid was prepared by cloning the prM/E expression cassette
from pCBWN (kindly provided by Mike Diamond, Washington University) into
the pVAX1 (Invitrogen) backbone. Five untreated BALB/c mice served as naive
control mice. The ethics committee of the faculty of Veterinary Medicine of Ghent
University authorized the animal experiments (permit EC2012/124). Two weeks
after the boost, blood was collected and splenocytes were isolated. Splenocyte
suspensions were depleted of red blood cells using ammonium chloride hypotonic
lysis and passed through a m cell strainer. To obtain enough splenocytes for CD4+
and CD8+ isolation, we pooled the splenocytes of the vaccinated as well as the
naive control mice, and subsequently divided the pooled cells into two cell
preparations. In the first preparation CD8+ T cells were depleted with magnetic
CD8 Dynabeads (Life Technologies, Merelbeke, Belgium) and in the other
preparation CD4+ cells were depleted with magnetic CD4 Dynabeads (Life
Technologies, Merelbeke, Belgium) in accordance with the manufacturer’s
recommended protocol. To confirm the depletion, spleen cells were stained with
PerCP-anti-CD4 (Biolegend, Uithoorn, The Netherlands) or PerCP anti-CD8
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(Biolegend, Uithoorn, The Netherlands) and analyzed by flow cytometry (Accuri
C6, BD Biosciences, Erembodegem, Belgium). The extent of depletion obtained
was 97% and 93% for respectively CD42 and CD8-depletion. Next, ELISPOT
assays were performed to measure the IFN-c and IL-4 production by CD4 and
CD8 depleted splenocytes. In detail, sterile 96-well Maxisorp immuno-plates were
coated with anti-IL-4 (Biolegend, Uithoorn, The Netherlands) or anti-IFN-c
monoclonal antibodies (Biolegend, Uithoorn, The Netherlands) and blocked with
sterile PBS containing 1% BSA for 1 h at 37 C˚. Next, 36105 CD82 or CD42
Table 1. An overview of used E-protein derived peptides and their characteristics.
Peptide n˚
E-protein
derived
peptides
MHC
class I
MHC
class II Expression
Domain within
WNV E protein
Sequences of
known human
T cell epitope
within our peptides References
15 M66-75/E1-20 2 I
16 E11-40 ++ I
17 E31-60 x 2 I/II
18 E51-80 x x + II
19 E71-100 ++ II
20 E91-120 x ++ II RGWGNGCGLFGKGSI [30, 31]
21 E111-140 x ++ II/I
22 E131-160 x 2 I
23 E151-180 x x ++ I
24 E171-200 ++ I
25 E191-220 x + I/II
26 E211-240 x + II TFLVHREWFMDLNLPW [13, 32]
27 E231-260 x ++ II
28 E251-280 x x + II
29 E271-300 x 2 II/I
30 E291-320 x + I/III EKLQLKGTTYGVCSKAFK [30]
31 E311-340 x + III
32 E331-360 x 2 III
33 E351-380 +/2 III
34 E371-400 x + III KVLIELEPPFGDSYIVV [31]
35 E391-420 x + III HKSGSSIGKAFTTTLKGA [31]
36 E411-440 x x 2 III SVGGVFTSV [33, 34, 35]
WDFGSVGGVFTSVGKAVH [13]
37 E431-460 x + III FRSLFGGMSWITQGLLGA [30]
38 E451-480 x + III FRSLFGGMSWITQGLLGA [30, 31]
39 E471-500 x x +/2 III
40 E491-501/NS11-18 + III
Amino acid sequences of the E-protein derived peptides used in this study, their expression level in E. coli, and the presence of predicted MHC class I or
class II epitopes in the different domains of the E-protein compared to known human T-cell epitopes. The sequence of the peptides can be found in
Chabierski et al. [24].
Abbreviations. E: WNV envelope protein, M: WNV membrane protein, NS: WNV non-structural protein ++: very high expression, +: high expression, +/2:
moderate expression and –: very low expression.
doi:10.1371/journal.pone.0115343.t001
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depleted splenocytes were plated in 100 ml of culture medium and stimulated
during 16h with culture medium with GST (negative control), g/mL
Concanavalin A (ConA, positive control, Sigma–Aldrich (Diegem, Belgium)),
2 mg/ml purified E-protein [25] or 2 mg/ml of purified recombinant GST-
peptides. After stimulation the plates were washed two times with PBS and four
times with PBS containing 0,05% Tween-20. IL-4 or IFN-c trapped on the plates
was detected by a biotinylated monoclonal anti-IL-4 (Biolegend, Uithoorn, The
Netherlands) or anti-IFN-c antibody (Biolegend, Uithoorn, The Netherlands).
Subsequent incubation with GABA-conjugated streptavidin (U-Cytech
Fig. 1. Expression and purification of recombinant GST tagged peptides. SDS-PAGE showing crude
lysates of protein-expressing bacteria and purification steps of peptide E471 showing a moderate expression
(a) and peptide E131 showing very low expression (b). Lane 1, crude lysate; lane 2, lysate supernatant after
centrifugation; lane 3, size marker; lanes 4–5, respectively elution fraction 1 and 2 of recombinant peptide
after glutathione affinity purification.
doi:10.1371/journal.pone.0115343.g001
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Biosciences, Utrecht, The Netherlands) was used to develop silver spots at places
where immune cells secreted IL-4 or IFN-c during stimulation. Splenocytes from
the vaccinated and non-vaccinated mice were analyzed in triplicate and the spots
were counted using the Bioreader 5000 (Bio-sys, Karben, Germany). IgG antibody
titers were determined as described by Oliphant et al. [25]. Briefly, two weeks after
the boost, blood samples were collected by cardiac puncture. Blood was allowed to
clot for 60 min at 37 C˚, and serum was obtained by combining the supernatant
from two successive centrifugations. The titers of E-specific IgG1 and IgG2a
antibodies in the serum were determined by ELISA in 96-well Maxisorp immuno-
plates (Nalge Nunc, Rochester, USA) coated overnight with recombinant E-
protein (1 mg/ml in carbonate buffer, 100 ml/well, 4 C˚). After coating, the plates
were washed three times with PBS containing 0.1% Tween-20 and blocked with
3% skim milk in PBS. Next, three-fold serial dilutions of mouse serum, starting
with a 1/100 dilution, were incubated for 1 h while shaking at room temperature.
After washing goat-derived anti-mouse serum conjugated with horseradish
peroxidase specific for mouse isotypes IgG1 or IgG2a (Southern Biotechnology
Associates, Birmingham, USA) and tetramethylbenzidine substrate (BD
Biosciences) were used to determine specific antibody titers. Antibody titers are
defined as the reciprocal of the highest dilution with an OD450 that is at least
double the OD450 of pre-immune serum samples.
To predict MHC class I and II T cell epitopes, we used the immune epitope
database (IEDB) analysis tool (http://www.iedb.org) [22]. The binding affinity of
peptides (15-mers) to MHC class II (H2-IEd and H2-IAd) was predicted. In this
case, the SMM-align method was employed to find out good MHC class II
candidate binders. The top scoring peptides were selected by setting cut-off values
of IC50 for the predicted binders at 250 nM. The MHC class I binding predictions
were made using the IEDB analysis resource Consensus tool, which combines
predictions from ANN aka NetMHC (3.4), SMM and Comblib. All the available
MHC alleles were selected and the peptide lengths were set at respectively 9, 10
and 12 for H2-Kd, H2-Dd and H2-Ld before making prediction. Strong binder to
selected MHC I alleles were classified based on the binding affinity thresholds
#50 nM. Overall, this computer driven algorithm predicted that 14 and 11 of the
E-protein derived peptides contained epitopes that were specific for respectively
MHC class I and II (Table 1). Interestingly, we found a clear difference of the
epitope distribution within the different structural domains of the E-protein.
Most of the epitopes located in domain III were peptides binding to MHC class I
molecules, whereas the majority of the epitopes located in domain II are peptides
that preferentially bind to MHC class II molecules (Table 1). Next, we wanted to
confirm that the predicted epitopes were indeed recognized by CD8+ or CD4+ T
cells. Therefore, we stimulated the CD42 or CD8-depleted splenocytes with the
purified E-protein derived peptides and measured the IFN-c and IL-4secretion via
ELISPOT assays. Twenty recombinant polypeptides were tested for their ability to
stimulate CD8+ or CD4+ spleen-derived T cells from BALB/c mice immunized
against WNV E-protein. As a negative control, splenocytes preparations from
naı¨ve mice were used. Out of the 14 predicted MHC class I epitopes we could
T Cell Epitope Mapping of the E-Protein of WNV in BALB/c Mice
PLOS ONE | DOI:10.1371/journal.pone.0115343 December 15, 2014 6 / 11
purify 12 peptides and, 11 were confirmed to be able to induce IFN-c secretion by
CD8+ T cells. However, peptide E391 that was also predicted to stimulate CD8+
cells did not stimulate IFN-c production. Interestingly, a new epitope (present in
peptide E211), for which the MHC class I restriction was not ascertained by the
IEDB analysis tool, was identified (Fig. 2a).
Peptides with atypical anchoring residues for a related MHC-I allele always
display very low binding affinity for MHC-I molecule and probably therefore
epitope E211 was not picked up by the IEDB analysis tool. However, some of these
peptides may possess potent antigenicity to induce robust and specific T cell
responses. The absence of an IFN-c response to the different peptides in naı¨ve
mice demonstrates the specificity of the anti-peptide responses observed. Brien et
al. identified six CD8 T cell epitopes in C57BL/6 mice by using overlapping WNV
15-mer peptides [14]. We identified more positive peptides most likely due to the
fact that we used 30-mer peptides and certain epitopes are present in two peptides
like e.g. H2-Dd epitope RSLFGGMSWI that is present in both peptides E431 and
E451. Fig. 3 depicts the location of our peptide sequences in the WNV E protein.
Some of our detected peptides match with T-cell epitopes that were identified
in WNV-infected humans (e.g. E91, E211, E291 (see also Table 1)). Additionally,
some of the peptides that elicited a strong IFN-c response are known epitopes for
neutralizing antibodies or belong to regions of the WNV E-protein that are very
important for the virus’s functionality. For example, peptide E91 is part of the
fusion loop domain [26], E291 and E311 are located in lateral ridge of domain III,
which has been shown to elicit virus-specific neutralizing antibodies [27], and
E431 is part of the stem-anchor region that is important in virus-cell membrane
fusion [28].
Surprisingly, we could not detect IL-4 responses in the CD4+ splenocytes with
any of the twenty purified peptides. Additionally, even when the full-length E
protein was used to stimulate the CD4+ cells we did not observe IL-4 production
(data not shown). On the other hand, immunized mice were able to raise
antibodies to the E-protein and a Th1-type response was noticed since higher
levels of IgG2a were obtained compared to the IgG1 levels (Fig. 2b). However,
with thirteen of the purified peptides we could detect a robust IFN-c response
after ex vivo stimulation of the CD4+ splenocytes (Fig. 2c). Only five of them were
predicted by the IEDB analysis tools. Two of the predicted peptides (18 and 25)
did not stimulate IFN-c secretion, whereas several new epitopes were identified in
the domain III of the E protein (peptides E291, E311, E371, E431). Since still 7%
of the CD8+ cells were not depleted in the CD4 splenocytes preparation it is
conceivable that some of the peptides detected may be restricted to MHC class I
molecules. However, the number of spots were reasonably higher compared to the
number of spots obtained in the CD8+ assays. On the other hand, since the
peptides are 30 amino acids long it is possible that they contain both CD4 and
CD8 epitopes. Indeed, Hughes et al. identified in C57/BL/6J mice a strong CD4+
epitope in WNV E between amino acids 466–495 [16] that had previously been
shown by Brien et al. [14] to contain a potent CD8+ T cell epitope with protective
T Cell Epitope Mapping of the E-Protein of WNV in BALB/c Mice
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cytotoxic capabilities. Peptide E231 specifically induced IFN-c production in
CD4+ splenocytes but not in CD8+ splenocytes.
One may notice that the number of spots obtained after stimulation of the
CD4+ and CD8+ T cells with WNV E protein is lower than after stimulation with
the purified GST fusion peptides (Fig. 2a and 2c). This can be explained as
follows. For the stimulation of the CD4+ and CD8+ T cells we used an equal
‘‘mass/volume’’ concentration of the E-protein and the purified recombinant
GST-peptides. However, the molecular weight of the E-protein (the ectodomain
was used in this study) is about twice that of the GST-peptides. Consequently, the
molar concentration of the GST-peptides was about twice the molar concentra-
tion of the E-protein. Thus, T cells stimulated with the GST-peptides were
exposed to a two-fold higher number of epitopes. This explains why the number
of spots after stimulation with the E-protein was lower.
Fig. 2. Detection of cellular and humoral immune response following pDNA-based vaccination. IFN-c production by (a) CD4-depleted and (c) CD8-
depleted splenocytes after stimulation with purified recombinant GST tagged E-protein derived peptides. The WNV E-protein specific T-cell repertoire in
BALB/c mice was expanded by two DNA vaccinations. Splenocytes obtained two weeks after the boost were stimulated with different recombinant GST
tagged E-protein derived peptides and the numbers of cells producing IFN-c were determined via ELISPOT. (b) Detection of serum IgG1 and IgG2a titers to
the WNV E-protein two weeks after the boost via ELISA.
doi:10.1371/journal.pone.0115343.g002
T Cell Epitope Mapping of the E-Protein of WNV in BALB/c Mice
PLOS ONE | DOI:10.1371/journal.pone.0115343 December 15, 2014 8 / 11
To conclude, to our knowledge this is the first study that describes a detailed
analysis of WNV E determinants recognized by CD4+ or CD8+ T cells in BALB/c
mice. We identified several CD8+ and CD4+ T cell epitopes in BALB/c mice
immunized against WNV E-protein by employing overlapping peptides spanning
the entire E-protein sequence. The DNA vaccine leads to the expression of
subviral particles that resemble WNV. Therefore, we can assume that the
identified epitopes will also exist during the course of a WNV infection.
Computer-assisted prediction of MHC peptide binding is a useful approach to
identify possible CD8+ epitopes, although we demonstrated that the accuracy of
these predictions must be verified empirically. Regarding the identification of
CD4+ T cell epitopes, the less strict binding requirements and thus the limited
predictive value of MHC class II motifs [29] makes this approach less suitable.
Only epitopes which are proven to stimulate CD4+ T cells in vitro or in vivo can
be used as potential subunit components for the design of vaccines against WNV.
Both the results of the cytokine profile produced by WNV-specific CD4+ T cells
and the IgG isotype suggest that the CD4 immune response after DNA vaccination
shows a Th1 bias.
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